Hidradenitis Suppurativa

The European Commission has granted marketing authorization for two devices that administer Bimzelx for the treatment of multiple inflammatory diseases, UCB announced in a press release.

Poor representation of darker skin tones in dermatology training materials has led to delayed diagnoses and worse treatment outcomes in Black, Asian and non-white Latin American patients, according to a presenter.

The Global Hidradenitis Suppurativa Atlas has produced a report offering the first global data on the diagnosis, impact and treatment of hidradenitis suppurativa, according to a press release.

CLEVELAND — Hidradenitis suppurativa research has hit roadblocks including high placebo responses and difficulty in accurate assessments, according to Amit Garg, MD, professor and chair of the department of dermatology at Northwell Health.

Patients treated with bimekizumab for moderate to severe hidradenitis suppurativa exhibited rapid and clinically meaningful responses that were maintained up to 48 weeks, according to new data published in The Lancet.

Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.

The European Commission has granted marketing authorization for Bimzelx to treat adults with active moderate to severe hidradenitis suppurativa, according to a UCB press release.

UCB has announced the launch of Make HStory, an educational campaign that provides resources on hidradenitis suppurativa to dermatologists as well as patients living with the disease, according to a press release.

Supplemental biologics license applications for Bimzelx for the treatment of hidradenitis suppurativa and a 2 mL autoinjector device for the drug have been accepted by the FDA, UCB announced in a press release.

In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed hidradenitis suppurativa research from the American Academy of Dermatology Annual Meeting, examining two studies into its treatment.